Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 47 of the 50 references it cites were found in a registry or an index.

Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models

Kulukian, Anita, Lee, Patrice, Taylor, Janelle, Rosler, Robert, de Vries, Peter, Watson, Daniel, Forero-Torres, Andres, Peterson, Scott·2020·Molecular Cancer Therapeutics

Published version of a preprint

Abstract

HER2 is a transmembrane tyrosine kinase receptor that mediates cell growth, differentiation, and survival. HER2 is overexpressed in approximately 20% of breast cancers and in subsets of gastric, colorectal, and esophageal cancers. Both antibody and small-molecule drugs that target HER2 and block its tyrosine kinase activity are effective in treating HER2-driven cancers. In this article, we describe the preclinical properties of tucatinib, an orally available, reversible HER2-targeted small-molecule tyrosine kinase inhibitor. In both biochemical and cell signaling experiments, tucatinib inhibits HER2 kinase activity with single-digit nanomolar potency and provides exceptional selectivity for HER2 compared with the related receptor tyrosine kinase EGFR, with a >1,000-fold enhancement in potency for HER2 in cell signaling assays. Tucatinib potently inhibits signal transduction downstream of HER2 and HER3 through the MAPK and PI3K/AKT pathways and is selectively cytotoxic in HER2-amplified breast cancer cell lines in vitro. In vivo, tucatinib is active in multiple HER2+ tumor models as a single agent and shows enhanced antitumor activity in combination with trastuzumab or docetaxel, resulting in improved rates of partial and complete tumor regression. These preclinical data, taken together with the phase-I tucatinib clinical trial results demonstrating preliminary safety and activity, establish the unique pharmacologic properties of tucatinib and underscore the rationale for investigating its utility in HER2+ cancers.

Overview

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-19-0873

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 50 references

Cited by

See all 227

Metadata

Authors
Kulukian, A., Lee, P., Taylor, J., Rosler, R., de Vries, P., Watson, D., Forero-Torres, A., & Peterson, S.
Affiliations
  • Seagen (United States) (US)
  • Array BioPharma (United States) (US)
  • Seattle Foundation (US)
  • 3Cascadian Therapeutics, Seattle, Washington.
  • 1Seattle Genetics, Bothell, Washington.
Venue
Molecular Cancer Therapeutics
Published
2020-04-01
Volume
19
Issue
4
Pages
976-987
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W3015126839
Cited by
222
References
50
Citations by year
2026: 36 · 2025: 25 · 2024: 40 · 2023: 41 · 2022: 38 · 2021: 31 · 2020: 11
FWCI
11.11
Type
journal article
Language
en
Open access
closed
Locations
  • Molecular Cancer Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Funders
Seattle Genetics
Topics
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Keywords
tucatinib, HER2, tyrosine kinase inhibitors, HER2-positive breast cancer, docetaxel combination, HER2 amplification, HER3 signaling, MAPK signaling, PI3K/Akt signaling, oral small-molecule inhibitor, anticancer activity, preclinical cancer models
MeSH terms
Trastuzumab, Docetaxel, Animals, Antineoplastic Combined Chemotherapy Protocols, Drug Evaluation, Preclinical, Female, Humans, Mice, Nude, Neoplasms, Oxazoles, Pyridines, Quinazolines, Tumor Cells, Cultured, Apoptosis, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Xenograft Model Antitumor Assays, Cell Proliferation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models. https://app.cochat.ai/papers/10.1158/1535-7163.mct-19-0873
The paper
Kulukian, A., Lee, P., Taylor, J., Rosler, R., de Vries, P., Watson, D., Forero-Torres, A., & Peterson, S. (2020). Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-19-0873

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.